The cost to UNICEF of Paxlovid – including Pfizer’s assumption that UNICEF keeps how much it’s kept secret – is still significant, says Dr. Philippe Duneton, director of the Department of Archeology at the WHO. In announcing its “recommendations” to Paxlovid, the WHO took the extraordinary steps of publicly criticizing Pfizer for “lack of clarity,” making it difficult to know which country have the drugs and what they cover.
“We need a better consensus on value,” he said. Duneton said.
Manufacturers often like to say that the terms of their sales contract are confidential so as not to confuse them with other buyers. Pfizer chief executive Albert Bourla announced last week that Paxlovid had become a “growth driver” for the company, using a “tiered pricing approach” in which low-income countries and represents Paxlovid on the contrary. -to-profit value.
In response to a question from The New York Times, Pfizer reported that he had been “deeply moved by the opinion of our partners,” adding, “We have good faith. hear and respond to many of their concerns. “
Both Pfizer and Merck have also taken steps to make affordable generic versions of their drugs available, signing agreements with Drug Patent Pool, which was developed during the global AIDS crisis. bring drugs to low- and middle-income countries. It took years, and battles between protesters and companies, to reach a consensus on HIV.
But the recommendation for the Covid vaccine does not apply to many middle-income countries, including much of Latin America and the regions of North Africa and Asia. The result, experts say, is that if both poor and rich countries are to enter, then the middle nations will have to negotiate with companies – or force manufacturers to change. their intellectual property.
To date, 36 companies from 12 countries have signed Paxlovid generic. Companies in India have already developed formulations of Paxlovid and molnupiravir. The expectation is that the two drugs will eventually be available in approximately 100 low- and middle-income countries, accounting for about half of the world’s population. Companies will not receive bills from sales when the WHO declaration of a pandemic as a global health emergency remains in effect.
Paul Schaper, director of federal law enforcement at Merck, said: “Due to the severity of the epidemic and the fact that vaccines have different penetrations, we think This is an important service that the company can do, “he said.